Search for: "Novartis Pharmaceuticals Inc"
Results 221 - 240
of 394
Sort by Relevance
|
Sort by Date
1 Mar 2011, 1:34 pm
Kuzinski (No. 10-459) and Novartis Pharmaceuticals Corp. v. [read post]
25 Feb 2011, 1:26 pm
KuzinskiDocket: 10-459Issue(s): (1) What deference is due to an agency interpretation of its own regulations when the interpretation departs from the agency’s prior position; and (2) whether the Second Circuit erred in its construction of the outside sales exemption of the Fair Labor Standards Act.Certiorari stage documents:Opinion below (2d Cir.)Petition for certiorariBrief in oppositionPetitioner's reply Title: Novartis Pharmaceuticals Corp. v. [read post]
15 Feb 2011, 5:26 pm
(FDA Law Blog) Diovan (Vasartan) – France: Novartis v Actavis – preliminary injunction for Valsartan confirmed (The SPC Blog) Diovan HTC (Valsartan) – Belgium: Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog) Lescol (Fluvastatin) – US: Novartis files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (GenericsWeb) Mucinex… [read post]
15 Feb 2011, 4:06 am
Universal Commc’ns of Miami, Inc., 591 F.3d 101, 106 (2d Cir.2010) (in resolving whether advertising sales director was an administrative or sales worker in the publishing industry “a careful consideration of [employer's] business model provides some clarity”). [read post]
13 Feb 2011, 9:08 pm
Mylan Pharmaceuticals Inc. et al. 1:11-cv-00127; filed February 10, 2011 in the District Court of Delaware • Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG • Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc. [read post]
9 Feb 2011, 8:02 pm
Novartis, a federal jury in New York ordered Novartis Pharmaceutical, Inc. to pay over $250 million in damages, including punitive damages, to current and former female Novartis employees who brought claims of gender discrimination, including FRD. [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New Jersey: Court precludes jury… [read post]
5 Jan 2011, 9:22 am
Novartis Pharmaceuticals Corp., Case No. 04-CV-9194 (S.D.N.Y.) following a seven-week trial in the Spring of 2010. [read post]
31 Dec 2010, 11:31 am
Novartis Pharmaceuticals Corp., DA 10-0029 slip op., at 30 (Mont. [read post]
29 Dec 2010, 2:57 am
Ferring Pharmaceuticals, Inc et al. [read post]
22 Dec 2010, 3:23 pm
The Food & Drug Administration’s citation of Novartis for Facebook content that lacked required pharmaceutical side-effect warnings and disclaimers, and the agency’s subsequent delay in release of social media “guidance” for pharma until Q1 2011. [read post]
22 Dec 2010, 3:01 am
TONOPAN – no likelihood of confusion: Novartis v OHMI – Sanochemia Pharmazeutika (TOLPOSAN) (Class 46) Vanos (Fluocinonide) – US: Patent infringement complaint filed following a Paragraph IV certification: Medicis Pharmaceutical Corp. v. [read post]
8 Dec 2010, 2:20 am
Allergan, Inc (Docket Report) Products Enbrel (Etanercept) – Israel: Patent status in question, in need of legislative fix (America-Israel Patent Law) Fabrazyme (Alpha-galactosidase) – US: Statements by KEI and others on NIH rejection of Fabrazyme march-in request (KEI) Intuniv (Guanfacine) – US: Impax confirms patent challenge relating to Intuniv (GenericsWeb) Lovenox (Enoxaparin) – US: Momenta sues Teva over claims relating to ways of manufacturing and analysing… [read post]
23 Nov 2010, 2:00 pm
The largest fiscal year 2010 False Claims Act recoveries came from the pharmaceutical and medical device industries, which accounted for $1.6 billion in settlements, including the $669 million from Pfizer Inc., $302 million from AstraZeneca, and $192.7 from Novartis Pharmaceutical Corporation. [read post]
17 Nov 2010, 3:48 pm
., DIRECTV, Inc. v. [read post]
3 Nov 2010, 7:00 am
Two years later, Momenta Pharmaceuticals Inc. and its partner Sandoz, part of Novartis AG, filed. [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
27 Oct 2010, 8:57 am
Other companies in the top 10 include Novartis Pharmaceuticals, Forest Laboratories and Teva Pharmaceuticals. [read post]
27 Oct 2010, 8:57 am
Other companies in the top 10 include Novartis Pharmaceuticals, Forest Laboratories and Teva Pharmaceuticals. [read post]
25 Oct 2010, 11:10 am
Coming forward to the present time, on October 14, 2010 Health Canada issued a MedEffect e-Notice, "ACLASTA (zoledronic acid 5mg/100mL) solution for intravenous infusion - Association with renal dysfunction - Novartis Pharmaceuticals Canada Inc. [read post]
